fda glp-1 compounding warning letters september 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers Moderna, Prime Medicine, UnitedHealth: Readout

While these studies provide compelling proof-of-concept, a notable translational gap exists

Obes Rev (2020) 21(10):e13046

It is important to remember that competition from new entrants can help drive down costs

Canadian employers also have various requirements when it comes to approvals for GLP-1 coverage, according to the IFEBP survey, with body mass index coming out on top: A major new cardiovascular study on glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is sharpening an already fraught question for Canadian employers: How far should group benefits go in funding expensive diabetes and obesity drugs that may need to be taken for years?